EICHOR
● Recruiting
A Study of HDM2020 in Patients With Advanced Solid Tumors
Condition: Solid Tumor · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
About this study
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.
This description comes directly from the study's public registry record.
Talk to the study team
Ruihua Xu · 86-020-87343468 · rhuaxu@163.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07098052